A MarketBeat host and analyst discuss five speculative penny stocks they believe have more upside than the market may be pricing in: Vaxart, TRX Gold, Datavault AI, MicroVision, and Atossa Genetics. The core pitch is that each has a visible catalyst or narrative—clinical progress, gold leverage, AI/data monetization, autonomous driving/LiDAR exposure, or near-term FDA events—but all come with very high execution risk and low fundamental visibility.
Watch on YouTube ›Get the market thesis, key claims, assets, contradictions, and follow-up questions from any financial video — then unlock a version personalized to your portfolio, watchlist, and favorite speakers.
This is a host-led MarketBeat segment built around a simple thesis: these five penny stocks are small, risky, and often unprofitable, but each has a story that could produce outsized upside if the narrative plays out. The discussion is explicit that penny stocks are largely speculative, and the hosts frame the list as names investors might otherwise avoid because of low revenue, weak profitability, limited analyst coverage, and volatile trading behavior. The first name is Vaxart (VXRT), a clinical-stage biotech trying to make vaccines into oral tablets instead of injections. The bullish case is that an oral format could reduce needle fear, improve convenience, lower logistics costs for mass immunization, and potentially create licensing opportunities if the platform gets FDA approval. …
Tactically, this is a high-volatility watchlist, not a clean setup: the only near-term edges come from catalysts, gold strength, and short-interest squeezes. Expect sharp swings and failed breakouts to be common.
Over the next few months, the winners will likely be the names that convert narrative into visible progress—FDA steps, production growth, or sustained sector momentum. If those confirmations do not appear, the group likely reverts to speculative trading fodder.
Structurally, the transcript says penny-stock upside exists where regulation, commodity leverage, or platform adoption can create asymmetry. The durable lesson is that the upside can be real, but only a small fraction of these stories will survive the execution test.
Data Vault AI's model of helping companies turn raw data into revenue-generating digital assets could deliver nearly 400% upside within 12 months per analyst estimates.
Analysts have set a $4 price target ( ~400% upside) but revenue visibility is cloudy and institutional ownership is under 1%.
Atossa Genetics has the largest upside of any stock on this list, with a consensus analyst price target of $6.33.
The company received two recent positive FDA events (orphan drug designation and a study may proceed letter) for its drug Indoxifen, and is covered by five analysts.
TRX Gold's profitability and growth are accelerating due to the higher spot price of gold making mining operations more profitable.
Higher gold prices improve margins and enable expansion for gold miners, similar to how high oil prices boost oil drillers.
What is the first penny stock on this list?
The first stock is Vaxart (VXRT), a clinical-stage biotech company trying to turn vaccines into oral tablets rather than injections. They have no approved products yet and no revenue, so it's pure speculation on their ability to get products through clinical trials.
Does TRX Gold have an operational mine underway right now?
Yes, they are actively mining gold right now, reflected in their last earnings report with revenue growing. They announced they're expanding operations and those are on schedule. The company is still not profitable yet but revenue is going up.
Would you expect those 100% volatility swings to be possible with the other names on this list too?
Yes, absolutely. Chris distinguishes between traders who can time entry/exit and long-term investors who buy and hold with conviction without trying to time the stock, saying the biggest gains can sometimes be made with that patient approach.
Unlock the full claims, asset map, scores, related transcripts, follow-up questions, and AI chat — shaped around your portfolio, watchlist, favorite speakers, and risks.
